Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: a promising surveillance marker of therapy?

Scand J Rheumatol. 2015;44(6):519-20. doi: 10.3109/03009742.2015.1069888. Epub 2015 Sep 17.

Authors

F C Moazedi-Fuerst¹, S M Kielhauser¹, J Hermann¹, M Meilinger², U Demel¹, M H Stradner¹, W B Graninger¹

Affiliations

¹ a Departments of Rheumatology and Immunology , Medical University Graz , Austria.
² b Departments of Pulmonology , Medical University Graz , Austria.

PMID: 26376839
DOI: 10.3109/03009742.2015.1069888

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Antinuclear / blood
Antibodies, Antinuclear / immunology
Antirheumatic Agents / therapeutic use*
Autoantibodies / blood*
Autoantibodies / immunology
Biomarkers / blood
DNA Topoisomerases, Type I / blood
DNA Topoisomerases, Type I / immunology
Dose-Response Relationship, Drug
Humans
Immunologic Surveillance
Rituximab / therapeutic use*
Scleroderma, Diffuse / blood
Scleroderma, Diffuse / drug therapy*
Scleroderma, Diffuse / immunology*
Sensitivity and Specificity
Time Factors
Treatment Outcome

Substances

Antibodies, Antinuclear
Antirheumatic Agents
Autoantibodies
Biomarkers
Rituximab
DNA Topoisomerases, Type I